等待开盘 11-18 09:30:00 美东时间
-0.005
-3.63%
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
今日重点评级关注:摩根大通:维持CytomX Therapeutics"超配"评级,目标价从11美元升至12美元;康托·菲茨杰拉德:维持Exodus Movement"超配"评级,目标价从15美元升至16美元
11-13 11:50
Amerx analyst Casey Ryan maintains Innoviz Technologies (NASDAQ:INVZ) with a Buy and lowers the price target from $2.77 to $1.58.
11-13 01:24
JP Morgan analyst Jash Patwa downgrades Innoviz Technologies (NASDAQ:INVZ) from Overweight to Neutral.
11-12 20:32
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 财务业绩:- 营业收入:2026财年第三季度营收为1,210万美元,低于公司预期,主要原因是某汽车客户将量产(SOP)时间线推迟至2027年,导致相关NRE(非经常性工程)里程碑收入延后。 - 国防业务收入:本季度国防业务(Perciz品牌)首次贡献营收,约占总营收的10%。 - 毛利率:本季度毛利率为负10.3%,主要由于营收规模低于预期所致。 - 现金及流动性:季末持有现金、现金等价物、短期存款及可交易证券合计约5,440万美元,且无长期债务。 - 现金使用情况:本季度经营活动及资本支出所用现金为2,140万美元,主要由于产能爬坡相关付款的时间安
11-12 13:00
Innoviz Technologies (NASDAQ:INVZ) lowers FY2026 sales outlook from $67.000 million-$73.000 million to $44.000 million-$46.000 million vs $70.000 million estimate.
11-11 20:05
Innoviz Technologies (NASDAQ:INVZ) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $12.098 mil...
11-11 20:01
In a letter to Innoviz, MAFAT recognizes the maturity, robustness, performance and scalability of Innoviz LiDARs and the precise sensing that can help defense systems, via a range of defense applications, see clearly, act faster, and potentially save lives. TEL AVIV, Israel, Sept. 17, 2026 /PRNewswi...
09-17 20:13
Former President & CEO of Rafael Advanced Defense Systems and Retired IDF Major General to Lead the Board of Directors as Innoviz Builds on Its Momentum in Defense and Homeland Security Mark...
08-31 20:00
Innoviz Technologies (NASDAQ:INVZ) affirms FY2026 sales outlook from $67.000 million-$73.000 million to $67.000 million-$73.000 million vs $70.000 million estimate.
08-05 19:04